secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2025-05-28T23:59:59+00:00
Accession:  0001193125-25-128680
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero/GSK Phase 3 PIVOT-PO trial for tebipenem HBr meets primary endpoint, stops early for efficacy
--------------------------------------------------------------------------------

- Tebipenem HBr met non-inferiority vs IV imipenem-cilastatin in 1,690 cUTI patients; IDMC recommended early stop.
- No new safety concerns; diarrhea and headache most common adverse events.
- GSK plans FDA filing in second half 2025; could be first oral carbapenem for cUTIs in US.
- cUTIs affect ~2.9M US cases/year with >$6B in healthcare costs; IV-only standard currently.
- Supported by BARDA funding and QIDP/Fast Track designations from FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312525128680/0001193125-25-128680-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312525128680/d903768d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-128680

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer